Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.
Bioactive lipids
COVID-19
Coronavirus
OEA
Oleoylethanolamide
Journal
Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
05
04
2020
revised:
08
04
2020
accepted:
10
04
2020
pubmed:
25
4
2020
medline:
2
7
2020
entrez:
25
4
2020
Statut:
ppublish
Résumé
The current outbreak of COVID-19 (coronavirus) has been identified by World Health Organization (WHO) as a global pandemic. With the emergence of the COVID-19 virus and considering the lack of effective pharmaceutical treatment for it, there is an urgent need to identify safe and effective drugs or potential adjuvant therapy in this regard. Bioactive lipids with an array of known health-promoting properties can be suggested as effective agents in alleviating acute respiratory stress induced by virus. The bioactive lipid amide, oleoylethanolamide (OEA), due to several distinctive homeostatic properties, including anti-inflammatory activities, modulation of immune response, and anti-oxidant effects can be considered as a novel potential pharmacological alternative for the management of COVID-19.
Identifiants
pubmed: 32327293
pii: S0188-4409(20)30475-6
doi: 10.1016/j.arcmed.2020.04.006
pmc: PMC7158763
pii:
doi:
Substances chimiques
Endocannabinoids
0
Oleic Acids
0
oleoylethanolamide
1HI5J9N8E6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
464-467Informations de copyright
Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.
Références
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
J Crohns Colitis. 2020 Sep 16;14(9):1334-1336
pubmed: 32215548
Viruses. 2019 Jan 09;11(1):
pubmed: 30634396
Pharmacol Res. 2020 Jun;156:104770
pubmed: 32217148
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Lancet. 2003 Oct 25;362(9393):1353-8
pubmed: 14585636
J Biomed Biotechnol. 2004;2004(3):156-166
pubmed: 15292582
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6301-11
pubmed: 26261506
Sci Rep. 2018 Oct 5;8(1):14881
pubmed: 30291258
Front Pharmacol. 2016 Sep 15;7:317
pubmed: 27695418
Arch Med Res. 2020 Apr;51(3):282-286
pubmed: 32229155
J Travel Med. 2020 May 18;27(3):
pubmed: 32186711
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3793-8
pubmed: 24567377
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Science. 2003 Jun 6;300(5625):1524-5
pubmed: 12791976
J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1276-83
pubmed: 2434758
Front Psychiatry. 2019 Feb 19;10:63
pubmed: 30837904
Sci Rep. 2016 Oct 10;6:34611
pubmed: 27721381
Immunology. 2008 Nov;125(3):344-58
pubmed: 18422969
Obes Rev. 2019 Jul;20(7):1057-1069
pubmed: 31111657
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Addict Biol. 2018 Nov;23(6):1242-1250
pubmed: 29178411
Life Sci. 2020 Jun 1;250:117583
pubmed: 32217117
Clin Exp Pharmacol Physiol. 2020 Apr;47(4):543-552
pubmed: 31868943
Prog Lipid Res. 2017 Jul;67:1-15
pubmed: 28389247
Adv Pharm Bull. 2018 Aug;8(3):479-487
pubmed: 30276145
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Neuroimmunomodulation. 2017;24(4-5):183-199
pubmed: 29151103
Diabetes Res Clin Pract. 2020 Apr;162:108118
pubmed: 32179126
Cell. 2020 Apr 16;181(2):223-227
pubmed: 32220310
World J Pediatr. 2020 Jun;16(3):223-231
pubmed: 32034659